Clinical Trial

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

Study acronym: Eluminate-1
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Trial Details
NCT Number NCT07662044
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus
Enrollment 800 participants
Start Date 2026-07-06
Primary Completion 2028-07-14 (estimated)
Study Completion 2028-07-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-23